Oser, Matthew G. http://orcid.org/0000-0003-2047-0969
MacPherson, David http://orcid.org/0000-0003-3729-907X
Oliver, Trudy G.
Sage, Julien http://orcid.org/0000-0002-8928-9968
Park, Kwon-Sik http://orcid.org/0000-0003-3346-9086
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA269990, P50CA228944-01A1, U24CA213274, CA231997, U01CA224293)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 19 October 2023
Revised: 18 December 2023
Accepted: 20 December 2023
First Online: 8 January 2024
Competing interests
: MGO reports grants (current and past) from Eli Lilly, Takeda, Novartis, BMS, and Circle Pharma. JS has equity in, and is an advisor for, DISCO Pharmaceuticals. TGO has a patent related to SCLC subtyping and reports grants from Auron Therapeutics. The other authors declare no competing interests.